



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/552,182	10/05/2005	Marcia L Kalish	6395-67856-06	6209
46135 7590 09/22/2008 KLARQUIST SPARKMAN, LLP 121 S.W. SALMON STREET SUITE 1600 PORTLAND, OR 97204				
EXAMINER				
PENG, BO				
ART UNIT		PAPER NUMBER		
1648				
MAIL DATE		DELIVERY MODE		
09/22/2008		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/552,182

Applicant(s)

KALISH ET AL.

Examiner

BO PENG

Art Unit

1648

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 09 June 2008.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 26-29, 36 and 41-59 is/are pending in the application.
- 4a) Of the above claim(s) 47-54 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 26-29, 36, 41-46 and 55-59 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☒ Other: Notice to Comply

DETAILED ACTION

1. The examiner of your application in the Patent and Trademark Office has been reassigned. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Bo Peng, Art Unit 1648.

Continued Examination under 37 CFR 1.114

2. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on June 9, 2008, has been entered.
3. Claims 1-25, 30-35 and 37-40 have been cancelled. Claims 26-29, 36 and 41-59 are pending. Claims 47-54 were previously withdrawn from consideration. Claims 26-29, 36, 41-46 and 55-59 are considered in this Office action. Applicant elected species of SEQ ID NOs: 1 and 14.

Sequence Listing

4. The CRF for sequence listing, submitted on November 15, 2007, is defective as indicated on the attached report from STIC. A corrected sequence listing and CRF are required.

Claim Rejections - 35 USC § 103

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(c), (f) or (g) prior art under 35 U.S.C. 103(a).

6. **(Prior rejection-withdrawn)** The rejection of Claims 26-29, 38, 44-45, 55, 57 and 59 under 35 U.S.C. 103(a) as being unpatentable over Simon, *et al.* (2001) in view of Tam (1988) and Bridon, *et al.* (1998), **is withdrawn** in favor of a new rejection.

7. **(Prior rejection-withdrawn)** The rejection of Claims 36, 41-43, 46, 56, and 58 under 35 U.S.C. 103(a) as being unpatentable over Simon, *et al.* (2001), Tam (1988), and Bridon, *et al.* (1998) as applied to claims 26-29, 38, 44, 55, 57, and 59 above, and further in view of Silvera, *et al.*, Hirsch, *et al.*, and Tsujimoto, *et al.*, **is withdrawn** in favor of a new rejection.

8. **(New rejection)** Claims 26-29, 36, 41-46 and 55-59 are rejected under 35 U.S.C. 103(a) as being unpatentable over Simon, *et al.* (AIDS Res. And Hum Retroviruses, 17(10):937-952, 2001, cited in IDS); in view of Guertler (6,566,513), Tam (PANS, 1988, cited in IDS), Kim (2001, cited in IDS).

9. Claims 26-29, 36 and 46 are drawn to an immunoassay construction to detect and differentiate amongst various SIVs, comprising a first substrate of a plurality of **detection** multiple antigenic peptides (MAPs) derived from the immunodominant region of SIV gp36/41, and a second substrate of a plurality of **differentiation** MAPs derived from gp120 V3 loop, wherein the detection MAP and the differentiation MAP each **comprises** a core matrix and at least two linear antigenic sequences bonded to the core matrix, each linear antigenic sequence **comprising** less than 16 amino acid residues, wherein at least one of the MPAs represent at least one SIV;

10. Claims 28 and 57 require that each linear antigenic sequence of MAPs **comprises** 5-15 amino acid residues;

Claims 41-44, 55, 56 and 58 require that the linear antigenic sequence of the detection MAP comprises SEQ ID NO: 1; and/or the linear antigenic sequence of the differentiation MAP comprises SEQ ID NO: 14; or a sequence at least 80% identity to SEQ ID NO: 1 or 14;

Claims 45 and 59 require that the immunoassay of Claim 26 or 29, wherein the detection MAP and differentiation MAP each comprise **four** linear antigenic sequences bound to their respective matrix.

MAPs are defined in the specification as each peptide conjugated to a core consisting of 2ⁿ amino groups of lysine covalently attached to the C-terminus of either a detection or

differentiation peptide thus presenting 2³ copies of each peptide per core.

11. Simon teaches an enzyme immunoassay in an ELISA format for detecting and differentiating amongst various SIVs using synthetic peptides derived from SIV gp36/41 as detection antigenic peptides, and peptides derived from SIV gp120 V3 loop as differentiation antigenic peptides, see e.g. Abstract. As shown in Table 1, Simon teaches a SIVcpz gp41/36 peptide detection antigenic peptide, which **comprises** a linear antigenic sequence 100% identical to amino acids 1 to 9 of the instant detection peptide SEQ ID NO: 1, and a SIVcpz V3 peptide **comprises** a linear antigenic sequence 100% identical to the instant differentiation peptide SEQ ID NO: 14, as shown in the sequence alignment below:

Simon gp41/36	LAVERYLQDQQILGLWGCSGKAVC
SEQ ID NO: 1	WGCSGKAVCYT

Simon V3 peptide:	NNTRGEVQIGPGMTFYNIENVVGDTRSA
SEQ ID NO: 14	RGEVQIGPGMTFYNI

Other SIV gp41/36, or V3 peptides listed in Table 1 have at least 80% identity to SEQ ID NO: 1 or SEQ ID NO: 14, respectively.

12. Simon teaches that both gp41/36 detection peptides and V3 differentiation peptides are effective for detecting and differentiating different strains of HIV and/or SIV, see e. g. Abstract. The gp41/36 detection peptides correctly identified all the test samples, with 98% specificity. The V3 differentiation peptides discriminated 206 HIV-1 group M, 98 group O, 12 group M-t-O, and 128 HIV-2 sera. In the primate field evaluation panel, both gp41/36 and V3 detected and discriminated all the WB-positive samples originating from monkeys infected with SIVcpz, SIVagm-ver, SIVmnd-1, SIVmnd-2, SIVdrl, or SIVsun. Simon teaches that this detection and

differentiation ELISA prove is useful for studies of lentivirus prevalence and diversity in human and non-human primates, and may also have the potential to detect previous un-described SIVs (see e.g. Abstract).

13. Simon does not teach an enzyme assay in MAP format comprising multiple SIV gp41/36 detection and V3 differentiation peptides.

14. Guertler provides teachings indicating that immunodominant cysteine loop region of gp41/gp36 of HIV and SIV are one of art-recognized regions particular important for diagnosis of different strains of HIV and SIV, see e. g. col. 4 and Table 1. Guetler teaches a 32-mer peptide SEQ ID NO:31 derived from the cysteine loop region of gp41/gp36 of SIV-CPZ, which comprises a linear antigenic sequence 100% iencitcal to the instant SEQ ID NO:1, see sequence alignment below: The underline C indicates cysteine residues of the cysteine loop.

Guertler	gp41/36	RLLAVERYLQDQQILGLWGCSGKAVCYTTVPW
SEQ ID NO: 1		WG <u>C</u> SGKAV <u>C</u> YT

15. Tam teaches MAP constructs, which contain a core matrix and multiple antigen peptides of 9-16 amino acids. Tam teaches that such highly-density MAP is highly antigenic (whole document).

16. Kim provides teachings indicating MAP constructs, which contain the multiple amino acid sequences same as the monomeric peptide, can improve antigenicity of the monomer short peptides in enzyme immunoassays, therefore increase the sensitivity of the enzyme immunoassay. Using a model short peptide of 13 amino acid residues derived from the V3-loop of HIV-I gp120, Kim demonstrates that MAPs composed of two, four, and eight branches of the V3 monomeric peptide have better antigenicity than monomeric peptide and the tandem repeats

(Abstract).

17. It would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the detection and differentiation enzyme immunoassay of Simon by using a MAP format as taught by Tam and Kim to increase the sensitivity of the assay.

MPEP § 2144.06 recites the conclusions of *In re Kerkhoven*, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA): "It is *prima facie* obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose...[T]he idea of combining them flows logically from their having been individually taught in the prior art."

The strongest rationale for combining references is a recognition, expressly or impliedly in the prior art or drawn from a convincing line of reasoning based on established scientific principles or legal precedent, that some advantage or expected beneficial result would have been produced by their combination. *In re Sernaker*, 217 USPQ 1, 5 - 6 (Fed. Cir. 1983). See MPEP 2144.

In the present case, the skilled artisan would have been motivated to use MAP format of detection/differentiation peptides of the prior art in an enzyme immunoassay for detecting SIVs, and have a reasonable expectation of success, given the utility of gp41/36 immunodominant region for detection of SIVs and highly variable and serogroup specific gp120 V3 loop for discrimination of SIV serogroups, as taught by Simon and Guertler, given the successes of detection/differentiation peptides of the prior art in detecting SIV as shown by Simon, and also given that MAP constructs can increase sensitivity of the assay as taught by Tam and Kim. It is within the ability of one of ordinary skill in the art to make MAP constructs comprising an antigenic sequence less than 16 mer from gp41/36 peptide or V3 peptides of the prior art as taught and shown by Tam and Kim. Thus, the instant invention was clearly *prima facie* obvious to one of ordinary skill in the art at the time the invention was made.

Conclusion

18. No claims are allowed.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bo Peng, Ph.D. whose telephone number is 571-272-5542. The examiner can normally be reached on M-F, 9-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell, Ph.D. can be reached on 571-272-0974. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

/Bo Peng/

Examiner, Art Unit 1648